STALICLA
STALICLA SA , today announced first patient enrolled in its Phase 1b clinical trial with STP1, a first in class precision medicine for patients within the autism spectrum disorder (ASD) Phenotype 1 subgroup (ASD-Phen1), a novel biological subgroup identified by STALICLA’s proprietary discovery platform. STP1 is a novel combination of compounds: a pan-PDE inhibitor with anti-inflammatory properties and a modulator of NKCC1, specifically targeting the biological dysregulations linked to ASD-Phen1.
Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders (NDDs) currently diagnosed based on core behavioral features, including persistent deficits in social communication and social interaction, restricted and repetitive patterns of behavior, interests, or activities. Significant impairment in daily functioning should also be present. Globally, ASD is highly prevalent and affects approximately 10 million patients in Europe and the United States and more throughout the world. There are no biological criteria for this diagnosis. ASD is characterized by high levels of clinical and genetic heterogeneity, supporting the existence of ASD biological subtypes requiring differential pharmacological treatment strategies.
By combining real-world patient data and its proprietary systems biology and AI-powered drug discovery platform called DEPI (Databased Endophenotyping Patient Identification), STALICLA is uncovering novel patterns of non-behavioral and biologically defined parameters amongst patients with ASD. STALICLA has already identified ASD Phenotype 1, a first subpopulation of patients with idiopathic ASD that can be identified by distinct multi-omics biomarkers. ASD Phenotype 1 is characterized by dysregulation of key intracellular pathways, transcription factors and immune factors. The most recent biomarker data related to ASD Phenotype 1 will be presented by STALICLA ahead of publication at the BRAIN Foundation Synchrony 2020 conference on December 12, 2020 (online).
“STALICLA is the first company developing precision medicine treatments for a biologically defined subgroup of patients with ASD. A diagnosis of autism must be integrated with other layers of data to capture biologically specific mechanisms, enabling the identification of precision drug candidates to improve on the outcome of clinical trials. STALICLA has built its DEPI drug discovery platform to achieve just this. By defining novel ASD phenotypes based on clinical signs and symptoms and not only on behaviors, STALICLA is creating a precision medicine approach to discovering and developing novel treatments for patients with ASD,” said Lynn Durham, M.Sc. Chief Executive Officer and founder of STALICLA.
“This Phase 1b study for STP1 marks the first time that a precision therapeutic will be investigated in patients with a non-monogenetic cause of ASD. While the trial progresses, STALICLA will continue to drive forward its proprietary and partnered programs to define additional ASD Phenotypes and advance a robust pipeline of therapeutic candidates for ASD and other NDDs,” said, Delphine Charvin, PhD, STALICLA’s Chief Scientific Officer.
“Despite the high prevalence of neurodevelopmental disorders in the U.S. and Europe, most NDDs are diagnosed and treated based on behavioral-based classification systems alone,” said Study Investigator, Craig Erickson, MD, Cincinnati Children’s Hospital Medical Center. “I look forward to investigating the potential of STP1 in the first clinically validated subpopulation of patients with idiopathic ASD.”
The double-blind, placebo-controlled, first-in-human study is being conducted at Cincinnati Children’s Hospital Medical Center in Cincinnati, Ohio. The primary objective of the trial is to evaluate the safety and tolerability of a two-week oral treatment with STP1 in adult patients who match the ASD-Phen1 clinical criteria. Two ascending dose cohorts of approximately 12 patients each will be enrolled. The study will also assess the pharmacokinetic and pharmacodynamic effects of STP1 and includes exploratory efficacy surrogate endpoints.
About ASD Phenotype 1
ASD Phenotype 1 (ASD-Phen1) is a subgroup of patients with autism spectrum disorder which has been identified by STALICLA’s platform and includes as many as 20% of the total ASD population with a non-monogenetic cause. ASD-Phen1 was first validated by an observational clinical trial conducted at the Greenwood Genetic Center (South Carolina, U.S.). ASD-Phen1 criteria were applied to a cohort of 313 patients with ASD. The study led to the identification of patients who matched the required clinical criteria and represented the first clinical validation of the ASD-Phen1 subgroup. Further biological characterization of ASD-Phen1 revealed a specific biological signature, or “fingerprint,” of the patient subgroup that was consistent with the signature proposed by STALICLA’s DEPI drug discovery platform.
About STP1
STALICLA’s investigational new drug, named STP1, is a first-in-class precision medicine being developed as part of the company’s proprietary pipeline for the treatment of ASD for patients within the Phenotype 1 subgroup (ASD-Phen1). STP1 is a novel combination of a pan-PDE inhibitor with anti-inflammatory properties and a modulator of NKCC1. STP1 was identified as a potential match for ASD Phenotype 1 using the DEPI platform, addressing ASD-Phen1 biological dysfunctions and limiting the emergence of compensatory disease pathways. In addition, STP1 has shown a good safety profile in nonclinical toxicology studies. Taken individually, both compounds have also demonstrated good clinical safety and tolerability profiles over a broad range of doses and non-ASD indications.
About STALICLA
STALICLA is reframing neurodevelopmental disorders on the basis of novel insights into their biological underpinnings. By combining real-world patient data and a proprietary systems biology and AI-powered drug discovery platform called DEPI, STALICLA is uncovering novel patient subgroups, enabling targeted clinical development and fueling a rich pipeline of precision therapies. STALICLA has formed a global network of partnerships to bring the first precision medicine treatments to patients with NDDs as efficiently as possible with an initial focus on autism spectrum disorder (ASD). https://stalicla.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005723/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H2SITE Strengthens Its Leadership With a New Control Room, Developed in Collaboration With Siemens, to Remotely Monitor Membrane Reactor and Separator Technologies for Hydrogen Production Across Europe27.10.2025 12:01:00 CET | Press release
H2SITE, the deep-tech start-up revolutionizing high-purity hydrogen production through cutting-edge palladium membrane technology, is scaling up its industrial presence with projects deployed across several European countries. To ensure performance and continuous optimization of its membrane reactors and separators, H2SITE has launched a control and data collection room built in collaboration with Siemens, based on the beta version of Siemens WinCC Unified Collaboration and Datahub software. The control room is already integrated and will be further developed across various ongoing and future projects, covering a wide range of market segments that reflect the versatility of H2SITE’s membrane-based technology. In the field of ammonia (NH₃) cracking, projects such as EIC, APOLO, and KATA are integrating this tool to monitor hydrogen production efficiency and system reliability in real time. Within the Waste-to-Hydrogen (WtH₂) segment, the HYIELD project is applying the control room to op
Comply Acquires Trailight to Accelerate Global Expansion and Create the Industry’s First Fully Integrated Firm and Employee Compliance Platform27.10.2025 10:07:00 CET | Press release
Comply, the leading provider of regulatory and compliance technology solutions for financial firms, today announced it has acquired Trailight, the U.K.’s leading provider of purpose-built solutions for managing conduct risk, competence frameworks, and global accountability regimes. With the addition of Trailight, Comply becomes the first and only unified compliance platform to bring together firm compliance, employee compliance, individual accountability regime and archiving solutions across jurisdictions. The acquisition strengthens Comply’s growing presence in Europe, where demand for modern, integrated compliance solutions continues to accelerate amid expanding regulatory frameworks and accountability mandates. “Over the past year, we’ve seen remarkable growth across Europe as firms seek to consolidate their compliance technology and gain greater transparency into both firm and employee obligations,” said Michael Stanton, CEO of Comply. “Trailight is the perfect complement to that s
Colorectal, Liver, and Lung Cancer Patients at Vinmec Experience Extended Survival with AIET Cell-Based Immunotherapy – Technology Transferred from Japan27.10.2025 07:39:00 CET | Press release
Vinmec Health System attracts international patients to Vietnam for treatment Significantly extended survival and improved quality of life (QoL) for cancer patients achieved through autologous cell-based AIET immunotherapy, utilizing patients' own natural killer (NK) cells and T cells, has positioned Vinmec Hospital, Vietnam, as an emerging medical tourism destination for cancer treatment across Asian countries. This accomplishment was presented by Professor Nguyen Thanh Liem at the NCRM NICHE 2025. He acknowledged the technology transfer support from GN Corporation, Japan, enabling the implementation of standardized AIET protocols in accordance with Japanese regulations, bringing treatment access to patients at Vinmec since 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251026088789/en/ Professor Nguyen Thanh Liem, Director, Institute of Stem Cell and Genetic Technology Research at Vinmec International Hospital, Hanoi
METI will hold GGX Finance Summit27.10.2025 07:30:00 CET | Press release
On November 5 (Wed), the Ministry of Economy, Trade and Industry (METI) will hold the GGX Finance Summit at The Capitol Hotel Tokyu and on-line. In order to further develop discussions on transition finance, industry decarbonization, and other topics related to how business and finance contribute to decarbonization, we will promote mutual cooperation between the government, business, and financial sectors, and hold discussions to lead the international rule-making process to achieve both emission reductions and economic growth. Outline of GGX Finance Summit Date: November 5th, 2025 10:00-16:45 (JST, GMT+9:00) Venue: The Capitol Hotel Tokyu (Tokyo) (2-10-3, Nagata-cho, Chiyoda-ku, Tokyo 100-0014, Japan) Organizer: Ministry of Economy, Trade and Industry (METI), GX Acceleration Agency Co-organizer: World Business Council for Sustainable Development (WBCSD), TCFD Consortium Format: Hybrid (On-site and on-line) Language: Japanese/English (with English/Japanese simultaneous interpretation)
NITMX, Ant International and Krungthai Bank Expand Payment Connectivity Between Thailand and China via PromptPay27.10.2025 04:37:00 CET | Press release
The parties will promote inbound payments via PromptPay and Alipay, an Alipay+ e-wallet partner, enabling more convenience for Chinese travellersPartnership builds on Alipay+’s efforts to support the tourism industry in Thailand and enable local merchants to connect with travellers from China and beyond Under the guidance of the Bank of Thailand, Ant International, a leading global digital payment, digitisation and financial technology provider and National ITMX will partner to enhance and promote payments connectivity via PromptPay, between Thai merchants and Chinese consumers, which will be launched soon. Krungthai Bank will be the settlement bank for this cross-border QR partnership. In the initial phase, Chinese travellers to Thailand can use Alipay, an Alipay+ e-wallet partner, to make QR payment at millions of local merchants by scanning the PromptPay QR. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251026429360/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom